Mortality at day 30 · AKI
Intensive showed no clear difference in mortality at day 30 compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality after 30 days post‐randomisation · AKI
Intensive showed no clear difference in mortality after 30 days post‐randomisation compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Patients free of RRT after discontinuing CRRT · AKI
Intensive showed no clear difference in patients free of RRT after discontinuing CRRT compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
2 findings from 1 review
Adverse events: hypophosphataemia · AKI
Intensive leads to higher adverse events: hypophosphataemia compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
1 finding from 1 review
Mortality: patients with sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients without sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients without sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients with AKI related to cardiac or general surgery · patients with AKI who need CRRT
Intensive leads to lower mortality: patients with AKI related to cardiac or general surgery compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
1 finding from 1 review
Mortality: patients with AKI not related to surgery · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with AKI not related to surgery compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Anxiety · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
1 finding from 1 review
no estimate extracted
180 participants
Very low
Depression · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
1 finding from 1 review
no estimate extracted
1412 participants
Very low
Overall survival · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
Less intensive showed no clear difference in overall survival compared with more intensive follow‐up after primary cancer treatment (low certainty).
1 finding from 1 review
HR 1.05 [0.96, 1.14]
10726 participants
Low